BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 31190985)

  • 1. Acute myeloid leukemia patient with
    Huang Y; Hu J; Lu T; Luo Y; Shi J; Wu W; Han X; Zheng W; He J; Cai Z; Wei G; Huang H; Sun J
    Cancer Manag Res; 2019; 11():4129-4142. PubMed ID: 31190985
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Tang S; Shen H; Mao X; Dai H; Zhu X; Xue S; Ding Z; Lu J; Wu D; Tang X
    Int J Hematol; 2017 Oct; 106(4):552-561. PubMed ID: 28616699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of FLT3-ITD with DNMT3A R882 double-mutation on the prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
    Tang SH; Lu Y; Zhang PS; Liu XH; Du XH; Chen D; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Pei RZ; Tang XW
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):552-557. PubMed ID: 30122013
    [No Abstract]   [Full Text] [Related]  

  • 5. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
    Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
    Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FLT3-ITD Allelic Ratio and NPM1 Mutation Do Not Impact Outcomes in Acute Myeloid Leukemia Patients with FLT3-ITD after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Propensity Score- Matching Study.
    Zhou C; Zheng F; Xu L; Zhang X; Chang Y; Mo X; Sun Y; Huang X; Wang Y
    Transplant Cell Ther; 2023 Jul; 29(7):456.e1-456.e11. PubMed ID: 37028555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
    Ahn JS; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):61-70. PubMed ID: 26234722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of low allelic ratio
    Sakaguchi M; Yamaguchi H; Najima Y; Usuki K; Ueki T; Oh I; Mori S; Kawata E; Uoshima N; Kobayashi Y; Kako S; Tajika K; Gomi S; Shono K; Kayamori K; Hagihara M; Kanda J; Uchiyama H; Kuroda J; Uchida N; Kubota Y; Kimura S; Kurosawa S; Nakajima N; Marumo A; Omori I; Fujiwara Y; Yui S; Wakita S; Arai K; Kitano T; Kakihana K; Kanda Y; Ohashi K; Fukuda T; Inokuchi K
    Blood Adv; 2018 Oct; 2(20):2744-2754. PubMed ID: 30341082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.
    Guièze R; Cornillet-Lefebvre P; Lioure B; Blanchet O; Pigneux A; Recher C; Bonmati C; Fegueux N; Bulabois CE; Bouscary D; Vey N; Delain M; Turlure P; Himberlin C; Harousseau JL; Dreyfus F; Béné MC; Ifrah N; Chevallier P;
    Am J Hematol; 2012 Dec; 87(12):1052-6. PubMed ID: 22911473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of haploidentical hematopoietic stem cell transplantation on comutations based on next-generation sequencing in adult acute myeloid leukemia patients with the FLT3-ITD mutation.
    Tang F; Zhao X; Ruan G; Jiang Q; Jiang H; Xu L; Wang Y; Zhang X; Liu K; Huang X
    Hematol Oncol; 2023 Oct; 41(4):733-742. PubMed ID: 37272204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic significance of early assessment of minimal residual disease in acute myeloid leukemia with mutated NPM1 patients].
    Zhao T; Zhu HH; Wang J; Jia JS; Yang SM; Jiang H; Lu J; Chen H; Xu LP; Zhang XH; Jiang B; Ruan GR; Wang DB; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):10-16. PubMed ID: 28219218
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
    Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G;
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia.
    Oran B; Cortes J; Beitinjaneh A; Chen HC; de Lima M; Patel K; Ravandi F; Wang X; Brandt M; Andersson BS; Ciurea S; Santos FP; de Padua Silva L; Shpall EJ; Champlin RE; Kantarjian H; Borthakur G
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1218-1226. PubMed ID: 27058617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations.
    Chou SC; Tang JL; Hou HA; Chou WC; Hu FC; Chen CY; Yao M; Ko BS; Huang SY; Tsay W; Chen YC; Tien HF
    Leuk Res; 2014 Nov; 38(11):1278-84. PubMed ID: 25260824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable long-term survival using consolidation chemotherapy without allogeneic hematopoietic cell transplantation for acute myeloid leukemia with wild-type
    Baek DW; Lee JM; Kim JH; Cho HJ; Ham JY; Suh JS; Sohn SK; Moon JH
    Blood Res; 2019 Sep; 54(3):189-197. PubMed ID: 31730679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients.
    Tien FM; Hou HA; Tsai CH; Tang JL; Chen CY; Kuo YY; Li CC; Lin CT; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Tseng MH; Liu MC; Liu CW; Lin LI; Chou WC; Tien HF
    Eur J Haematol; 2018 Jul; 101(1):86-94. PubMed ID: 29624746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
    Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
    Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLT3-ITD and CEBPA Mutations Predict Prognosis in Acute Myelogenous Leukemia Irrespective of Hematopoietic Stem Cell Transplantation.
    Wang H; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    Biol Blood Marrow Transplant; 2019 May; 25(5):941-948. PubMed ID: 30503388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia.
    Wakita S; Marumo A; Morita K; Kako S; Toya T; Najima Y; Doki N; Kanda J; Kuroda J; Mori S; Satake A; Usuki K; Ueki T; Uoshima N; Kobayashi Y; Kawata E; Nakayama K; Nagao Y; Shono K; Shibusawa M; Tadokoro J; Hagihara M; Uchiyama H; Uchida N; Kubota Y; Kimura S; Nagoshi H; Ichinohe T; Kurosawa S; Motomura S; Hashimoto A; Muto H; Sato E; Ogata M; Mitsuhashi K; Ando J; Tashiro H; Sakaguchi M; Yui S; Arai K; Kitano T; Miyata M; Arai H; Kanda M; Itabashi K; Fukuda T; Kanda Y; Yamaguchi H
    Cancer Sci; 2023 Apr; 114(4):1297-1308. PubMed ID: 36610002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.